The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated axial spondyloarthritis pathway.
Treatment pathway is available on separate guidelines page.
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve Ixekizumab as a treatment option for the treatment of ankylosing spondylitis or active non-radiographic axial spondyloarthritis in line with NICE TA718. The current spondyloarthritis treatment pathway is attached below.
Ixekizumab for this indication will be considered as RED on the traffic light status (treatment should be initiated and continued by specialist clinicians).
Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.”
